Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
Primary Purpose
Pediculosis
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Spinosad
Spinosad
Permethrin 1%
Sponsored by
About this trial
This is an interventional treatment trial for Pediculosis focused on measuring Human Head lice
Eligibility Criteria
Inclusion Criteria:
- Subjects must have an active head lice infestation present at Day 0.
- Subjects can be female or male, at least 6 months of age.
- Subjects must be in good general health based on medical history.
- Each subject must have an appropriately signed Informed Consent agreement. Subjects under the age of 12 must also provide written or oral assent.
- The subject/caregiver must be able to read English or Spanish at a 7th grade level.
- The parent or guardian within a household must be willing to allow other household members to be screened for head lice. If other household members are found to have a head lice infestation, they should also be enrolled in the study.
- Subjects must agree to not use any other form of lice treatment during the course of the study and must agree not to use any of the excluded concomitant medications.
- Subjects must agree not to cut or chemically treat their hair in the period between the initial treatment and the final visit.
- Subjects/caregiver must demonstrate a clear understanding of his/her requirements for study participation and agree to comply with study instructions.
Exclusion Criteria:
- Individuals with history of irritation or sensitivity to pediculicides or hair care products.
- Individuals with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel or Sponsor, will interfere with the evaluation.
- Individuals who require treatment with topical salicylic acid, topical corticosteroids, anthralin, vitamin D analogs, retinoids, immunosuppressants, topical hair growth formulations, and topical dandruff treatments.
- Infested subjects who have been previously treated with a pediculicide within the 48 hours prior to the study.
- Individuals with a condition or illness that, in the opinion of the Investigator, may compromise the objective of the protocol.
- Individuals receiving systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel or study monitor may interfere with the study results.
- Individuals who have participated in a clinical trial within the past 30 days.
- Individuals (or individuals from households) who, in the opinion of the Investigator, do not understand the requirements for study participation and/or may be likely to exhibit poor compliance.
- Individuals with household members who are infested with lice but are unwilling or unable to enroll in the study or to use the standard course of lice treatment.
- Females who are pregnant or nursing. Females of childbearing potential must have a negative urine pregnancy test prior to treatment at Day 0. If a household has a pregnant female with an active case of head lice, the entire household is excluded from participation. If the pregnant household member does not have lice, this individual must NOT be the caregiver (one who provides treatment to other household members).
- Sexually active females not using effective contraception.
- Individuals who have a history of drug abuse in the past year.
Sites / Locations
- Hill Top Research
- Burke Pharmaceutical Research
- Impact Clinical Trials
- DMI Healthcare Group
- Hill Top Research
- Haber Dermatology & Cosmetic Surgery
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
A - NatrOVA 1% - no nit combing
B - NatrOVA 1% - nit combing required
C - NIX
Arm Description
NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
NIX Creme Rinse (permethrin 1%) applied to Over the Counter (OTC) Instructions for Use
Outcomes
Primary Outcome Measures
Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice
The primary efficacy endpoint was the proportion of primary subjects in the enrolled households who were lice free (no live lice, adults or nymphs), as assessed by the trained evaluator, 14 days after the last treatment (i.e., Day 14 for subjects who treated once and Day 21 for subjects who treated twice).
Secondary Outcome Measures
Evaluation of the Safety of NatrOVA Creme Rinse - 1% Based Upon Reported Adverse Events and Observed Skin/Scalp Reactions.
To evaluate the safety of NatrOVA® 1% Creme Rinse based upon reported adverse events and observed skin/scalp reactions. Additional safety assessments included cutaneous/ocular irritation.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00545753
Brief Title
Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
Official Title
A Phase 3 Comparative Safety and Efficacy Study Between NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects >6 Months of Age or Older With Pediculosis Capitis
Study Type
Interventional
2. Study Status
Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
March 2008 (Actual)
Study Completion Date
May 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ParaPRO LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A comparative safety and efficacy study of NatrOVA Creme Rinse - 1% versus NIX Creme Rinse, under actual use conditions in subjects 6 months of age or greater who are infested with Pediculosis capitis (human head lice).
Detailed Description
This is a Phase 3 multi-site, randomized, evaluator/investigator-blinded, three-arm, parallel group study evaluating the safety and efficacy of NatrOVA Creme Rinse - 1% (with nit combing and without nit combing) versus NIX Creme Rinse in an "actual use" environment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pediculosis
Keywords
Human Head lice
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
558 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A - NatrOVA 1% - no nit combing
Arm Type
Experimental
Arm Description
NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
Arm Title
B - NatrOVA 1% - nit combing required
Arm Type
Experimental
Arm Description
NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
Arm Title
C - NIX
Arm Type
Active Comparator
Arm Description
NIX Creme Rinse (permethrin 1%) applied to Over the Counter (OTC) Instructions for Use
Intervention Type
Drug
Intervention Name(s)
Spinosad
Other Intervention Name(s)
Natroba (spinosad) Topical Suspension, 0.9%
Intervention Description
10 minute topical application product, following by a complete rinse off.
Intervention Type
Drug
Intervention Name(s)
Spinosad
Other Intervention Name(s)
Natroba (spinosad) Topical Suspension, 0.9%
Intervention Description
10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
Intervention Type
Drug
Intervention Name(s)
Permethrin 1%
Other Intervention Name(s)
NIX Creme Rinse
Intervention Description
Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
Primary Outcome Measure Information:
Title
Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice
Description
The primary efficacy endpoint was the proportion of primary subjects in the enrolled households who were lice free (no live lice, adults or nymphs), as assessed by the trained evaluator, 14 days after the last treatment (i.e., Day 14 for subjects who treated once and Day 21 for subjects who treated twice).
Time Frame
Assessment were made 14 days following the final product treatment
Secondary Outcome Measure Information:
Title
Evaluation of the Safety of NatrOVA Creme Rinse - 1% Based Upon Reported Adverse Events and Observed Skin/Scalp Reactions.
Description
To evaluate the safety of NatrOVA® 1% Creme Rinse based upon reported adverse events and observed skin/scalp reactions. Additional safety assessments included cutaneous/ocular irritation.
Time Frame
Participants were followed for a minimum of 14 days (1 treatment) and a maximum of 21 days (2 treatments)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subjects must have an active head lice infestation present at Day 0.
Subjects can be female or male, at least 6 months of age.
Subjects must be in good general health based on medical history.
Each subject must have an appropriately signed Informed Consent agreement. Subjects under the age of 12 must also provide written or oral assent.
The subject/caregiver must be able to read English or Spanish at a 7th grade level.
The parent or guardian within a household must be willing to allow other household members to be screened for head lice. If other household members are found to have a head lice infestation, they should also be enrolled in the study.
Subjects must agree to not use any other form of lice treatment during the course of the study and must agree not to use any of the excluded concomitant medications.
Subjects must agree not to cut or chemically treat their hair in the period between the initial treatment and the final visit.
Subjects/caregiver must demonstrate a clear understanding of his/her requirements for study participation and agree to comply with study instructions.
Exclusion Criteria:
Individuals with history of irritation or sensitivity to pediculicides or hair care products.
Individuals with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel or Sponsor, will interfere with the evaluation.
Individuals who require treatment with topical salicylic acid, topical corticosteroids, anthralin, vitamin D analogs, retinoids, immunosuppressants, topical hair growth formulations, and topical dandruff treatments.
Infested subjects who have been previously treated with a pediculicide within the 48 hours prior to the study.
Individuals with a condition or illness that, in the opinion of the Investigator, may compromise the objective of the protocol.
Individuals receiving systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel or study monitor may interfere with the study results.
Individuals who have participated in a clinical trial within the past 30 days.
Individuals (or individuals from households) who, in the opinion of the Investigator, do not understand the requirements for study participation and/or may be likely to exhibit poor compliance.
Individuals with household members who are infested with lice but are unwilling or unable to enroll in the study or to use the standard course of lice treatment.
Females who are pregnant or nursing. Females of childbearing potential must have a negative urine pregnancy test prior to treatment at Day 0. If a household has a pregnant female with an active case of head lice, the entire household is excluded from participation. If the pregnant household member does not have lice, this individual must NOT be the caregiver (one who provides treatment to other household members).
Sexually active females not using effective contraception.
Individuals who have a history of drug abuse in the past year.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bill Miller, MD
Organizational Affiliation
Concentrics Research
Official's Role
Study Director
Facility Information:
Facility Name
Hill Top Research
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85251
Country
United States
Facility Name
Burke Pharmaceutical Research
City
Hot Springs
State/Province
Arkansas
ZIP/Postal Code
71913
Country
United States
Facility Name
Impact Clinical Trials
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
DMI Healthcare Group
City
Largo
State/Province
Florida
ZIP/Postal Code
33773
Country
United States
Facility Name
Hill Top Research
City
Miamiville
State/Province
Ohio
ZIP/Postal Code
45147
Country
United States
Facility Name
Haber Dermatology & Cosmetic Surgery
City
South Euclid
State/Province
Ohio
ZIP/Postal Code
44118
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
We'll reach out to this number within 24 hrs